

STUDY

Efficacy of guselkumab in treating regional psoriasis and psoriatic arthritis: post-hoc analyses of VOYAGE 1 and 2

Population: N = 335

Primary endpoint at W16 and W24:

- Scalp-specific Investigator's Global Assessment
- Hand and/or foot Physician's Global Assessment
- Fingernail Physician's Global Assessment
- Nail Psoriasis Severity Index
- Dermatology Life Quality Index

Eligibility: Enrolled in VOYAGE 1 and 2 trial; diagnosed with plaque psoriasis for ≥6 months with or without PsA; IGA ≥3; PASI ≥12; body surface affected by psoriasis ≥10%; self-reported PsA. **Exclusion:** Prior use of guselkumab or adalimumab within last 3 months

TRIAL DESIGN

Phase III randomized, placebo, active controlled VOYAGE 1 and 2 trials

Treatment arm 1
n = 153



Guselkumab | 100 mg: W0, W4, then Q8W

Treatment arm 2
n = 106



Adalimumab | 80 mg: W0 | 40 mg: W1, then Q8W


Control arm
n = 76



Placebo




Guselkumab | 100 mg: W16, W20, then Q8W




EFFICACY W0-16

*vs control: p < 0.001

†vs control: p = 0.005



EFFICACY W16-24



SAFETY

The types and frequencies of AEs in the PsA cohort were consistent with those reported for the overall studies.

Guselkumab offers deep and durable responses, with meaningful improvements in nail, scalp, and palmoplantar psoriasis in patients with psoriasis and PsA at Week 16 of treatment compared with placebo.

Abbreviations: AE, adverse event; DLQI, Dermatology Life Quality Index; f-PGA, fingernail Physician's Global Assessment; hf-PGA, hand and/or foot PGA; IGA, Investigator's Global Assessment; NAPSI, Nail Psoriasis Area and Severity Index; PASI, Psoriasis Area and Severity Index; ss-IGA, scalp-specific IGA; PsA, psoriatic arthritis; Q8W, every 8 weeks; Q2W, every 2 weeks; W, week.

Orbai AM, et al. *Dermatol Ther (Heidelb)*. 2023;13(11):2859-2868.